HPLC-MS/MS测定利多卡因中痕量基因毒性杂质

    Determination of Trace Genotoxic Impurity in Lidocaine by HPLC-MS/MS

    • 摘要:
      目的 建立一种高效液相色谱-三重四极杆质谱联用(HPLC-MS/MS)方法,用于测定利多卡因中基因毒性杂质N-亚硝基-去乙基利多卡因N-(2,6-dimethylphenyl)-2-ethyl(nitroso)amino acetamide,NDLC。
      方法 采用资生堂 C18(150 mm×4.6 mm,5 μm)色谱柱,以0.020 mol·L−1乙酸铵溶液-乙腈(90∶10)为流动相A,乙腈为流动相B,程序洗脱,进样器温度5 ℃,流速1.0 mL·min−1,柱温30 ℃,进样体积10 μL。质谱采用正离子电喷雾离子源,多反应监测模式,监测离子对为m/z 236.2→105.1(定量离子对)和m/z 236.2→58.1(定性离子对),标准曲线法定量。
      结果 NDLC浓度在1.058~21.160 ng·mL−1内线性关系良好,相关系数(r)为0.999 7;检测限0.349 ng·mL−1,定量限1.058 ng·mL−1,平均回收率99.1%,RSD为1.5%。应用该方法对3批利多卡因原料药中的NDLC进行测定,检出量在1.9~2.9 ng·g−1,未超过可接受限度。
      结论  所建方法灵敏、准确,各项方法学验证结果均满足痕量检测要求,可应用于利多卡因中NDLC的测定,可为工艺监控与质量控制提供有效支持。

       

      Abstract:
      OBJECTIVE To develop a high-performance liquid chromatography-triple quadrupole mass spectrometry (HPLC-MS/MS) method for the determination of the genotoxic impurity N-(2,6-dimethylphenyl)-2-ethyl(nitroso)amino acetamide(NDLC) in lidocaine.
      METHODS Chromatographic separation was achieved on a Shiseido C18 column(150 mm×4.6 mm, 5 μm) using a mobile phase consisting of 0.020 mol·L−1 ammonium acetate solution-acetonitrile (90∶10) as mobile phase A and acetonitrile as mobile phase B with gradient elution. The autosampler temperature was maintained at 5 ℃ with a flow rate of 1.0 mL·min−1. The column temperature was set at 30 ℃, and the injection volume was 10 μL. Mass spectrometric detection was carried out using a positive-ion electrospray ionization source in multiple reaction monitoring mode. The monitored ion transitions were m/z 236.2→105.1(quantitative ion pair) and m/z 236.2→58.1(qualitative ion pair). Quantification was carried out using the standard curve method.
      RESULTS The method demonstrated a linear range of 1.058–21.160 ng·mL−1 for NDLC with a correlation coefficient(r) of 0.999 7. The limit of detection and limit of quantification were 0.349 ng·mL−1 and 1.058 ng·mL−1, respectively. The average recovery was 99.1% with RSD of 1.5%. The method was successfully applied to the determination of NDLC in 3 batches of lidocaine bulk drug, with detected levels ranging from 1.9–2.9 ng·g−1, which did not exceed the acceptable limit.
      CONCLUSION The developed method is sensitive, accurate, and all validation results meet the requirements for trace analysis. It has been successfully applied to the determination of NDLC in lidocaine, and can provide effective support for process monitoring and quality control.

       

    /

    返回文章
    返回